Health Care·Life Sciences Tools & Services·$21.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.02 | N/A | -95.35% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.02 | N/A | -95.35% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions affecting performance. They did not provide any forward guidance, indicating uncertainty.
Management acknowledged the significant EPS miss and indicated ongoing challenges.
They did not provide specific guidance for future quarters.
West Pharmaceutical's earnings report shows a significant miss on EPS, which reflects ongoing challenges the company is facing. Despite this, the stock saw a slight increase of 0.25%, possibly due to market factors or investor sentiment rather than performance. The lack of guidance adds to the uncertainty surrounding the company's future outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EDWARDS LIFESCIENCES
Oct 26, 2015